Alpha Tau Medical Ltd. (DRTS)
Market Cap | 253.27M |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
Shares Out | 69.01M |
EPS (ttm) | -0.98 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 41,285 |
Open | 3.62 |
Previous Close | 3.69 |
Day's Range | 3.60 - 3.74 |
52-Week Range | 3.00 - 20.65 |
Beta | n/a |
Analysts | Buy |
Price Target | 17.60 (+379.56%) |
Earnings Date | Mar 27, 2023 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price forecast is $17.6, which is an increase of 379.56% from the latest price.
News

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023
JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, a...

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™...

Alpha Tau to Present at Upcoming November Investor Conferences
JERUSALEM, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge -

OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative
NEW YORK--(BUSINESS WIRE)--OurCrowd, a leading global venture firm, announced today the launch of a Global Health Equity Fund (GHEF) in collaboration with the WHO Foundation. The news was shared at th...

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Al
– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American Soc...

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Pete...

Alpha Tau Medical to Participate in Upcoming September Investor Conferences
JERUSALEM, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Compan...

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
- Received FDA Conditional Investigational Device Exemption (IDE) , whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT ™ in recurrent cutaneous squamous cell carcino...

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and M...

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced...

Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™
JERUSALEM , June 22, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the firs...

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC
JERUSALEM , June 8, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, an...

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors
JERUSALEM , June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaR...

Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds- -Targeted start of U.S. multi-center pivotal trial in skin canc...

First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer Trial
JERUSALEM , May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW) , the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first p...

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update
JERUSALEM, March 28, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha Da...

12 Stocks Halted On A Circuit Breaker This Week
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and br...

Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd.

Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsore...

Healthcare Capital Corp Announces Special Meeting Date for Proposed Business Combination with Alpha Tau Medical Ltd.
NEW YORK, New York and JERUSALEM, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp (NASDAQ: HCCC, HCCCW, and HCCCU) (“HCCC”) today announced that on January 12, 2022, the U.S. Securit...

Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
JERUSALEM, Jan. 3, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by H...

Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
JERUSALEM, Nov. 3, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first ...

Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Primary Objective
JERUSALEM, Oct. 25, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot trial for sk...

Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid Tumors Through the Precision Delivery of Alpha Radiation
- Alpha Tau's proprietary Alpha DaRT™ is designed to deliver uniquely potent alpha radiation to destroy solid tumors with localized precision, sparing surrounding healthy tissue, thereby maintaining c...